BR112016011778A8 - pirazol fluorofenila, seus usos, e composição farmacêutica - Google Patents

pirazol fluorofenila, seus usos, e composição farmacêutica

Info

Publication number
BR112016011778A8
BR112016011778A8 BR112016011778A BR112016011778A BR112016011778A8 BR 112016011778 A8 BR112016011778 A8 BR 112016011778A8 BR 112016011778 A BR112016011778 A BR 112016011778A BR 112016011778 A BR112016011778 A BR 112016011778A BR 112016011778 A8 BR112016011778 A8 BR 112016011778A8
Authority
BR
Brazil
Prior art keywords
pyrazole
fluorophenyl
pharmaceutical composition
group
och3
Prior art date
Application number
BR112016011778A
Other languages
English (en)
Other versions
BR112016011778A2 (pt
Inventor
Zhou Guoqiang
Kun-Chin Liu Kevin
Wu Liang
Xie Yinong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112016011778A2 publication Critical patent/BR112016011778A2/pt
Publication of BR112016011778A8 publication Critical patent/BR112016011778A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

a presente invenção refere-se a um composto da fórmula: em que x é selecionado do grupo que consiste em , , , , e ; r é selecionado do grupo que consiste em h e ch3; r1 é selecionado do grupo que consiste em h, ch3, f, cl, och3, c(o)oh, c(o)nh2 e ; ou um sal farmaceuticamente aceitável do mesmo.
BR112016011778A 2013-12-19 2014-12-11 pirazol fluorofenila, seus usos, e composição farmacêutica BR112016011778A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2013/089987 WO2015089800A1 (en) 2013-12-19 2013-12-19 Fluorophenyl pyrazol compounds
PCT/US2014/069785 WO2015094913A1 (en) 2013-12-19 2014-12-11 Fluorophenyl pyrazol compounds

Publications (2)

Publication Number Publication Date
BR112016011778A2 BR112016011778A2 (pt) 2017-08-08
BR112016011778A8 true BR112016011778A8 (pt) 2018-01-30

Family

ID=52355187

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016011778A BR112016011778A8 (pt) 2013-12-19 2014-12-11 pirazol fluorofenila, seus usos, e composição farmacêutica

Country Status (23)

Country Link
US (1) US9499490B2 (pt)
EP (1) EP3083605B1 (pt)
JP (1) JP6190067B2 (pt)
KR (1) KR101827660B1 (pt)
CN (1) CN105814039B (pt)
AU (1) AU2014366436B2 (pt)
BR (1) BR112016011778A8 (pt)
CA (1) CA2929563C (pt)
DK (1) DK3083605T3 (pt)
EA (1) EA029058B1 (pt)
ES (1) ES2664418T3 (pt)
HR (1) HRP20180618T1 (pt)
HU (1) HUE039102T2 (pt)
LT (1) LT3083605T (pt)
MX (1) MX2016007985A (pt)
NO (1) NO3083605T3 (pt)
PL (1) PL3083605T3 (pt)
PT (1) PT3083605T (pt)
RS (1) RS57071B1 (pt)
SA (1) SA516371323B1 (pt)
SI (1) SI3083605T1 (pt)
TR (1) TR201802981T4 (pt)
WO (2) WO2015089800A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI582083B (zh) 2014-10-07 2017-05-11 美國禮來大藥廠 胺基吡啶基氧基吡唑化合物
JP6626885B2 (ja) * 2014-10-31 2019-12-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新しいピリジニルオキシ及びフェニルオキシピラゾリル化合物
WO2016131198A1 (en) * 2015-02-18 2016-08-25 Eli Lilly And Company Pyrazole compounds
WO2016201662A1 (en) * 2015-06-18 2016-12-22 Eli Lilly And Company Fluoropyridyl pyrazol compounds
CN109096194B (zh) * 2018-10-09 2022-02-08 湖南师范大学 一种双胍衍生物、药物组合物、制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7989400A (en) * 1999-10-01 2001-05-10 Smithkline Beecham Corporation Compounds and methods
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
WO2002078699A1 (en) * 2001-03-29 2002-10-10 Smithkline Beecham Corporation Compounds and methods
EP1434772A4 (en) * 2001-10-12 2005-05-04 Smithkline Beecham Corp CONNECTIONS AND METHODS
WO2003051906A2 (en) * 2001-12-14 2003-06-26 Smithkline Beecham Corporation Compounds and methods
CN1678608A (zh) 2002-07-02 2005-10-05 先灵公司 新的神经肽yy5受体拮抗剂
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
DE102004049078A1 (de) * 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
WO2010065879A2 (en) * 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
TW201245155A (en) 2010-09-01 2012-11-16 Du Pont Fungicidal pyrazoles
WO2012090219A2 (en) * 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
JP2014518853A (ja) * 2011-04-28 2014-08-07 ブリストル−マイヤーズ スクイブ カンパニー 新規な二環式窒素含有ヘテロアリールｔｇｒ５受容体調節因子
TWI582083B (zh) 2014-10-07 2017-05-11 美國禮來大藥廠 胺基吡啶基氧基吡唑化合物

Also Published As

Publication number Publication date
RS57071B1 (sr) 2018-06-29
US9499490B2 (en) 2016-11-22
SA516371323B1 (ar) 2018-04-24
US20160289195A1 (en) 2016-10-06
EP3083605B1 (en) 2018-02-21
TR201802981T4 (tr) 2018-03-21
AU2014366436B2 (en) 2017-08-24
PT3083605T (pt) 2018-03-01
CA2929563C (en) 2018-05-15
HRP20180618T1 (hr) 2018-07-13
JP2016540801A (ja) 2016-12-28
PL3083605T3 (pl) 2018-07-31
NO3083605T3 (pt) 2018-07-21
HUE039102T2 (hu) 2018-12-28
JP6190067B2 (ja) 2017-08-30
LT3083605T (lt) 2018-04-10
KR101827660B1 (ko) 2018-02-08
DK3083605T3 (en) 2018-03-12
CN105814039B (zh) 2018-07-17
WO2015089800A1 (en) 2015-06-25
WO2015094913A1 (en) 2015-06-25
EP3083605A1 (en) 2016-10-26
AU2014366436A1 (en) 2016-05-19
SI3083605T1 (en) 2018-04-30
EA029058B1 (ru) 2018-02-28
EA201690924A1 (ru) 2016-09-30
CN105814039A (zh) 2016-07-27
BR112016011778A2 (pt) 2017-08-08
KR20160075827A (ko) 2016-06-29
CA2929563A1 (en) 2015-06-25
ES2664418T3 (es) 2018-04-19
MX2016007985A (es) 2016-09-09

Similar Documents

Publication Publication Date Title
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
BR112017017396A2 (pt) derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112015032921A8 (pt) compostos de benzofuranila e benzoxazolila substituídos e utilizações dos mesmos
BR112014017749A8 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
IN2014CN04530A (pt)
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.
BR112012032087A2 (pt) composto, medicamento, e, uso de um composto
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112015021524A2 (pt) derivados de sulfonil quinolina e usos dos mesmos
BR112016011778A8 (pt) pirazol fluorofenila, seus usos, e composição farmacêutica
BR112015016325A2 (pt) Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo
BR112015029348A8 (pt) inibidores da bace, seus usos, e composição farmacêutica
BR112015023829A2 (pt) composto de amidina e seu uso
MX364400B (es) Compuestos de tetraciclina.
BR112015029504A2 (pt) inibidores quinase
BR112014026198A2 (pt) compostos pirazol como inibidores de sglt1
BR112018010107A2 (pt) composição farmacêutica para o tratamento ou prevenção de nash
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
EA201600394A1 (ru) Трициклические соединения пиперидина

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2544 DE 08-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.